Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P30044 (
antioxidant enzyme
)
8,037
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The potential effects of oil specimens both related and unrelated to cases of Toxic Oil
Syndrome
(TOS) on the phospholipid fatty acid composition, some
antioxidant enzyme
activities, and lipid peroxidation in guinea pig liver microsomes were investigated. For 4 weeks, animals were fed diets supplemented with either oil related to cases of TOS or control oil, previously heated or not. In all cases, the fat diet produced the incorporation of approximately 7% of linoleic acid exclusively in the phosphatidylethanolamine (PE) of liver microsomes. A pronounced increase in lipid peroxidation products, measured as malondialdehyde (MDA) and 4-hydroxyalkenals, was detected in animals fed nonheated control oil. Heated oil diets produced significant increases in superoxide dismutase and glutathione peroxidase activities with concomitant decreases in the lipid peroxidation status. Heated oils also increased the oleic/stearic acid ratio in the phosphatidylserine plus phosphatidylinositol (PS + PI) fraction. This ratio was also increased in the same fraction from animals fed non heated case oil. The study shows that case oil produces a decrease in the lipid peroxidation products with minimal alterations in phospholipid fatty acid composition of liver microsomes, which is dependent rather on the composition of dietary fat than on toxic effects.
...
PMID:Phospholipid fatty acid and lipid peroxidation in liver microsomes from guinea pigs fed oil related to the toxic oil syndrome. 982 23
Oxidative stress may be involved in the pathophysiology of schizophrenia. No double-blind study has compared the effects of typical and atypical antipsychotics on both
antioxidant enzyme
activity and nitric oxide (NO) levels in schizophrenic patients. Seventy-eight inpatients with chronic schizophrenia were randomly assigned to 12 weeks of treatment with 6 mg/day of risperidone or 20 mg/day of haloperidol using a double-blind design. Clinical efficacy was determined using the Positive and Negative
Syndrome
Scale. Blood superoxide dismutase (SOD) and plasma NO levels were measured in patients and 30 normal controls. Our results showed that following a 2-week washout period, levels of SOD and NO were significantly increased in patients with schizophrenia compared to normal controls. Both risperidone and haloperidol equivalently reduced the elevated blood SOD levels in schizophrenia, but neither medication reduced the elevated plasma NO levels in schizophrenia. Low blood SOD levels at baseline predicted greater symptom improvement during treatment, and greater change in SOD was correlated with greater symptom improvement. These results suggest that both typical and atypical antipsychotic drugs may at least partially normalize abnormal free radical metabolism in schizophrenia, and some free radical parameters at baseline may predict antipsychotic responses of schizophrenic patients.
...
PMID:Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. 2222 58